mg-study-page_v1.0 2026-03-02
Note: This is NOT a clinical trial. This is a research-only initiative collecting data for scientific understanding rather than testing treatments.
Help shape the future of Myasthenia Gravis care.
Living with MG? You have expertise researchers need.
Join our study.
Participate from home to help build a next-generation patient registry that keeps you linked to your samples, clinical information, and other contributions, powering research to improve care for everyone with MG.
About this study
Impactful science depends on keeping participants informed and involved.
AminoChain is launching an at-home study to create a next-generation, connected patient registry that links your samples, disease history, and genomic data into a living virtual biorepository that pairs clinical information with stored materials to enable deeper, more useful research into Myasthenia Gravis (MG).
Grounded in transparency and supported by privacy first technology, this study will give participants a clear window into how their contributions are used, providing the foundation for staying informed and meaningfully engaged as the science advances.
Participants will stay connected to their contributions, receive study updates, and be part of the journey to better understand MG.
Who Can Participate
You may qualify if you are:
18 years and over and live in the United States
Have a confirmed diagnosis of Myasthenia Gravis (MG)
Willing to self-collect a small blood sample at home using an approved device
The study is also enrolling a small group of healthy controls matched by age and sex.
Age
18 years and over
Diagnosis
Myasthenia Gravis (MG)
Residence
United States
Compensation
Up to 250$
What To Expect
Upon enrollment, participants will be guided to provide small at-home blood sample for immune and genetic analysis. The data will help identify biomarkers that could inform future diagnostic tools and therapies.
Your Window Into Research
Stay connected to your research journey through the AminoChain Donor Portal - a secure and transparent platform to view your participation history, updates on ongoing and future studies, and earn rewards for continued participation.
AminoChain’s protocol infrastructure ensures that your data and samples remain verifiable, secure, and connected to you, laying the groundwork for more trustworthy biomedical research.
The Team Behind This Study
AminoChain and ImYoo Health have come together to advance patient-centered research in Myasthenia Gravis. By combining secure research technology with deep clinical experience and close partnership with the MG community, we are working to make research more inclusive, equitable, and focused on what truly matters to patients.
Myasthenia Gravis (MG) & Study FAQ
What is Myasthenia Gravis (MG)?
Myasthenia Gravis is a rare autoimmune disorder that disrupts nerve-to-muscle communication, causing muscle weakness and fatigue in the eyes, face, throat, and limbs. MG occurs when immune system antibodies target receptors needed for muscle contractions, such as the acetylcholine receptor (AChR).
How is Myasthenia Gravis treated?
Is this a clinical trial?
Who runs this study?
What happens to my sample?
How long does participation take?
How is compensation provided?
How is my privacy protected?
Can I withdraw from this study?
Will I receive individual results?
